OptimizeRx Co. (NASDAQ:OPRX) Receives $10.38 Average PT from Brokerages

OptimizeRx Co. (NASDAQ:OPRX) has been given a consensus recommendation of “Moderate Buy” by the eleven analysts that are covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $10.38.

A number of analysts recently commented on the stock. JMP Securities boosted their target price on shares of OptimizeRx from $11.00 to $14.00 and gave the stock a “market outperform” rating in a report on Tuesday, May 13th. Roth Capital reiterated a “buy” rating on shares of OptimizeRx in a report on Tuesday, May 13th. Stifel Nicolaus boosted their target price on shares of OptimizeRx from $8.00 to $12.50 and gave the stock a “buy” rating in a report on Tuesday, May 13th. Wall Street Zen upgraded shares of OptimizeRx from a “hold” rating to a “buy” rating in a report on Thursday, May 22nd. Finally, B. Riley reiterated a “buy” rating on shares of OptimizeRx in a report on Tuesday, May 13th.

OptimizeRx Trading Up 3.1%

Shares of NASDAQ:OPRX opened at $14.62 on Monday. The company has a 50 day moving average of $9.98 and a 200-day moving average of $7.26. The firm has a market cap of $270.40 million, a P/E ratio of -10.99 and a beta of 1.34. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $15.25. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings results on Monday, May 12th. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.19. OptimizeRx had a negative net margin of 27.41% and a negative return on equity of 4.92%. The company had revenue of $21.93 million during the quarter, compared to analyst estimates of $18.69 million. As a group, analysts anticipate that OptimizeRx will post -0.33 earnings per share for the current fiscal year.

Insider Activity

In other news, Director James Paul Lang purchased 321,408 shares of the business’s stock in a transaction dated Friday, March 14th. The shares were acquired at an average price of $7.60 per share, for a total transaction of $2,442,700.80. Following the completion of the acquisition, the director now directly owns 389,452 shares of the company’s stock, valued at $2,959,835.20. The trade was a 472.35% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 5.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers increased its stake in OptimizeRx by 10.5% in the 1st quarter. Rhumbline Advisers now owns 27,785 shares of the company’s stock valued at $241,000 after buying an additional 2,636 shares during the period. Parkman Healthcare Partners LLC acquired a new position in OptimizeRx in the 1st quarter valued at approximately $4,114,000. AWM Investment Company Inc. increased its stake in OptimizeRx by 18.6% in the 1st quarter. AWM Investment Company Inc. now owns 255,421 shares of the company’s stock valued at $2,212,000 after buying an additional 40,000 shares during the period. Trexquant Investment LP acquired a new position in OptimizeRx in the 1st quarter valued at approximately $470,000. Finally, MetLife Investment Management LLC acquired a new position in OptimizeRx in the 1st quarter valued at approximately $99,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.